Pomalidomide
- Generic Name
- Pomalidomide
- Brand Names
- Imnovid, Pomalyst, Imnovid (previously Pomalidomide Celgene), Pomalidomide Viatris, Pomalidomide Zentiva, Pomalidomide Krka, Pomalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C13H11N3O4
- CAS Number
- 19171-19-8
- Unique Ingredient Identifier
- D2UX06XLB5
- Background
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
- Indication
Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also indicated for the treatment of Kaposi's sarcoma (KS) in AIDS patients who have failed highly active antiretroviral thera...
- Associated Conditions
- Kaposi's Sarcoma, Multiple Myeloma (MM)
- Associated Therapies
- -
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 15
- Registration Number
- NCT05556616
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸Scripps Health, San Diego, California, United States
A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment
- Conditions
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT05556798
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 810
- Registration Number
- NCT05519085
- Locations
- 🇺🇸
Hattiesburg Clinic Hematology/Oncology, Hattiesburg, Mississippi, United States
🇺🇸Astera Cancer Care, East Brunswick, New Jersey, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone
- Conditions
- Interventions
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 33
- Registration Number
- NCT05509374
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
- Conditions
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 810
- Registration Number
- NCT05455320
- Locations
- 🇺🇸
University of Kansas, Westwood, Kansas, United States
🇺🇸The Ohio State University Wexner Medical Center - James Cancer Hospital, Columbus, Ohio, United States
🇺🇸OhioHealth, Columbus, Ohio, United States
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Rajshekhar Chakraborty, MD
- Target Recruit Count
- 53
- Registration Number
- NCT05451771
- Locations
- 🇺🇸
New York Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States
🇺🇸Mayo Clinic Rochester, Rochester, Minnesota, United States
🇺🇸Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
A Study of Daratumumab
- Conditions
- Interventions
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 500
- Registration Number
- NCT05438043
- Locations
- 🇺🇸
University of Miami Sylvester Cancer Center, Miami, Florida, United States
🇺🇸Barnes-jewish Hospital, Saint Louis, Missouri, United States
🇧🇪ZNA Stuivenberg, Antwerpen, Belgium
PVd Versus Vd in NDMM Patients With RI
- Conditions
- Interventions
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 79
- Registration Number
- NCT05432414
- Locations
- 🇨🇳
Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM
- Conditions
- Interventions
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Registration Number
- NCT05408026
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
- Conditions
- Interventions
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 531
- Registration Number
- NCT05405166
- Locations
- 🇺🇸
Arizona Oncology Associates, PC - HAL- Site Number : 8400015, Prescott Valley, Arizona, United States
🇺🇸Rocky Mountain Cancer Centers, LLP- Site Number : 8400021, Aurora, Colorado, United States
🇺🇸Mayo Clinic- Site Number : 8400008, Jacksonville, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.